



A BRIEF REVIEW ON MUCORMYCOSIS

TEJASHRI . K. AHIRE,

DEPARTMENT OF PHARMACOLOGY

Swami Vivekananda sanstha's Institute of pharmacy, Mungase, Malegaon.

Corresponding Author: PROF. I. K. SONAWANE

ABSTRACT:

Angio invasive infection called mucormycosis is brought on by the fungus mucorales. Although it is a rare condition, immunocompromised persons are more frequently identified with it.

The major goal and objective of this review was to provide an overview of mucormycosis as well as details on medications and treatments for the condition.

Keywords :

Mucormycosis, Fungal infection, Antifungal drug, causative agent.

INTRODUCTION :

The term "Mucormycosis" was created by American pathologist R.D. Baker. It also goes by the name Zygomycosis. It can be described as an elusive fungus infection brought on by Mucorales members as well as zygomycotic species.

The Mucormycotina are frequent saprobes that come from rotting food soils or substance. Mucorales infections are Rapid progression-based classification(1)

History :

In the 1980s and 1990s, mucormycosis rates rapidly rose, mainly in immunocompromised people. Accordingly, a study was conducted based on the prevalence rate in France, which revealed an The German doctor Paltauf initially identified the condition as Mycosis Mucorina in 1885, which is when annual amplification of 7.4%. It was also claimed that mucorales can have seasonal variations and occur all over the world.(2)

EPIDEMIOLOGY:

Case reports and case series are where the majority of the information on the epidemiology of mucormycosis is found. Roden et al. published the first comprehensive evaluation of the literature in 2005.(3)

The analysis included 929 cases that were published between 1940 and 2003, and while it included entomophthoramycosis cases, it also contained 929 cases of the disease. More recently, 851 instances were

examined by Jeong et al. authored between 2000 and 2017. The PRISMA reporting framework was used to conduct and report the review in this study. guidelines guidelines for (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and only cases resulting from Mucorales (4)

On a nationwide level or in patients with certain underlying conditions, such as hematopoietic stem cell transplantation, other relatively sizable case series were gathered. Despite their inherent drawbacks, registries are a useful source of information. 230 cases from Europe were published in 2011 by the Working Group on Zygomycosis of the European Confederation of Medical Mycology (ECMM) and the International Society of Human and Animal Mycology (ISHAM). This registry was created in 2004.(5)

Pathogenes :

When a spore enters the body through the environment, polymorph nuclear phagocytes assist in the phagocytosis of mucous membranes. The fungus manifests itself in the body by eliminating unhealthy situations including acidity and immune cells Hyperglycemia also makes phagocytic activity more active. The enzyme ketone reductase, an enzyme necessary for fungus to develop they are secreted in an acidic environment. The fungus then enters arteries by absorbing all the iron in the serum and generates blood clots and tissue damage, which lead to angiogenesis by jor. The organisms now enter the endothelium cells. Cell and extracellular matrix, which is the most significant phase in pathogenesis. When mucorals enter, there is epithelial interaction. body epithelial cells are the ones that fight back.(6 The pathogenesis of mucormycosis is represented in fig no 1





Fig no.1 Pathogenes

Classification

Generally, mucormycosis is classified into five main types according to the part of the affected.(7)(8).

- 1) Sinuses and the brain (rhinocerebral); most prevalent in diabetics with uncontrolled blood sugar levels and in kidney transplant recipients.(7)
- 2) Lungs (pulmonary); the most common type of mucormycosis in people with cancer and in people who have had an organ transplant or a stem cell transplant(7)
- 3) Stomach and intestine (gastrointestinal); more common among young, premature, and low birth weight infants, who have had antibiotics, surgery, or medications that lower the body's ability to fight infection(7)
- 4) Widespread (disseminated); when the infection spreads to other organs via the blood(7)(9)

Sign and symptoms




The signs and symptoms of mucormycosis depend on where the infection has spread throughout the body. Infection typically starts in the mouth or nose and travels to the eyes, where it enters the central nervous systems. One-sided eye pain or headache may be one of the symptoms and signs of a fungal infection that starts in the nose or sinus and spreads to the brain. These symptoms and signs may also be accompanied by pain in the face, numbness, fever, loss of smell, a blocked nose, or a runny nose. The individual might appear to have sinusitis.(11).

One side of the face could appear bloated, and the upper inside of the mouth or across the nose may have fast growing "black lesions." Vision may appear blurry in one eye and it may appear enlarged and bulging.(12)

When the lungs are affected, symptoms including fever, coughing up blood, pain in the chest, and difficulty breathing might happen. When the gastrointestinal tract is affected, symptoms such as a stomachache, nausea,

vomiting, and bleeding may appear. Due to tissue loss, affected skin may look as a darkish reddish sensitive patch with a deepening centre. There might be an ulcer, and it might hurt a lot. (13).

A blood supply loss from an invasion of the blood vessels can cause thrombosis, which then causes the surrounding tissue to die. It can be challenging to determine whether symptoms are caused by widespread (disseminated) mucormycosis because it frequently affects persons who are already ill from other medical diseases. People who have a disseminated brain infection may have changes in their mental state or go into a coma. (14)



Where it comes from :-

The fungi that cause mucormycosis are found in the environment.

The fungus that cause mucormycosis, known as mucormycetes, are found in all parts of the environment, but they are most prevalent in soil and around decomposing organic materials, such as leaves, compost piles, and animal dung. They occur more frequently in soil than in air, and in the summer and fall as opposed to the winter or spring. It's probably difficult to totally avoid coming into touch with mucormycetes since the majority of humans come into contact with minute fungus spores every day. Most humans are not harmed by these fungus. Breathing in mucormycete spores, however, can result in an infection in the lungs or sinuses that can spread to other regions of the body in persons with compromised immune systems. (14)(15)

Causative Agent

There are 261 species in 55 genera that make up the order Mucorales, 38 of which have been linked to infections in humans. Due to molecular phylogenetic investigations, their taxonomy has altered significantly in recent years, and several taxa have unavoidably experienced many name changes. (17).

In Table 1, the taxonomic nomenclature of these species is shown.(21

Current Species Names	Previous Names/Synonyms
<i>Lichtheimia corymbifera</i>	<i>Absidia corymbifera, Mycocladus corymbifer</i>
<i>Lichtheimia ornata</i>	<i>Absidia ornata</i>
<i>Lichtheimia ramosa</i>	<i>Absidia ramosa, Mycocladus ramosus</i>
<i>Mucor ardhlaengiktus</i>	<i>Mucor ellipsoideus, Mucor circinelloides f. circinelloides</i>
<i>Mucor circinelloides</i>	<i>Rhizomucor regularior, Rhizomucor variabilis var. regularior</i>
<i>Mucor griseocyanus</i>	<i>Mucor circinelloides f. griseocyanus</i>
<i>Mucor irregularis</i>	<i>Rhizomucor variabilis</i>
<i>Mucor janssenii</i>	<i>Mucor circinelloides f. janssenii</i>
<i>Mucor lusitanicus</i>	<i>Mucor circinelloides f. lusitanicus</i>
<i>Rhizopus arrhizus</i> (incl. var. <i>delemar</i>)	<i>Rhizopus oryzae</i>
<i>Rhizopus microsporus</i>	<i>Rhizopus microsporus</i> var. <i>azygosporus</i> , var. <i>chinensis</i> , var. <i>oligosporus</i> , var. <i>rhizopodiformis</i> , var. <i>tuberosus</i>

Table NO 1

By inhalation, ingestion, or direct injection, the fungus spores penetrate the human body. a majority *Rhizopus arrhizus* is a widespread species worldwide (formerly *Rhizopus oryzae*). others alone Fungi fall under the genera *Saksenaea*, *Apophysomyces*, *Cunninghamella*, *Mucor*, *Rhizomucor*, and *Lichtheimia*. *Actinomucor*, *Syncephalastrum*, and *Cokeromyces*. In this comprehensive review, Jeong et al. *Rizopus* species, *Lichtheimia* species including *Mucor* species represented 75% of all instances.(18).

The mucormycosis-causing substances change based on the location. *Rhizopus* spp., *Lichtheimia* spp., and *Mucor* spp. were all isolated in the ECMM study from Europe, respectively in 34%, 19%, and 6% of the cases. The RetroZygo research from In France, 52% of cases were caused by *Rhizopus* species, and the second most frequent genus was (29%) *Lichtheimia* The second-most often isolated agents in Indian studies were species of *apophysomyces*. Almost always, cutaneous infections are caused by *Apophysomyces* and *Saksenaea* species. mucormycosis is primarily common in Asia and affects immunocompetent people. emerging species are developing, including *Saksenaea erythrospora*, *Thamnostylum lucknowense*, *Mucor irregularis*, and *Rhizopus homothallicus*.(19)(20)(21).

Treatment :-**Antifungal agents :-****Polyenes**

Antifungal medications, Amphotericin B in a lipid formulation, the novel triazolespo-saconazole, and echinocandins combined with Amphotericin B are all part of the treatment for mucormycosis (AMB). Amphotericin B is the only antifungal medication that has been licenced for the treatment of mucormycosis.

First-line antifungal options for mucormycosis

Drug	Recommended dosage	Advantage and supporting studies	Disadvantage
AMB	1.0-1.5 mg/kg/day	>5 decades clinical experience, only licensed agent for treatment of mucormycosis.	Highly toxic, poor CNS penetration
LAMB	5-10 mg/kg/day	Improved CNS penetration compared to AMB	Expensive
ABLC	5-7.5 mg/kg/day	Less nephrotoxic than AMB; murine and retrospective clinical data suggest benefit of combination therapy with echinocandins	More nephrotoxic than LAMB

Lipid formulations of Amphotericin B

AMB is the drug of preference for mucormycosis primary therapy. Significant in vitro MICs for AMB have been re-identified despite the absence of interpretive breakpoints for AMB. clinical isolates of Cunninghamella species were found in. Amphotericin B's MIC of 0.5 g/mL was closely related. substantially higher 6-week results in a small study of non-Asper-invasive gillsmouldinfections. As is the case with many antifungal medications and mycoses, the proper dosage for AMB and its formulations against mucormycosis is still unknown. As stated by according to current guidelines, the typical daily dose of LAMB (Lipid formulations of ABLC (Amphotericin B Lipid Complex) and Amphotericin B) are each 5 mg/kg/day .(22)(23)

New triazoles :

Triazoles function by eradicating ergosterol from fungi's cell membrane. Triazole anti-fungals fluconazole, itraconazole, and voriconazole have little or no effect on Mucorales. Two more recent triazoles, posaconazole and isavuconazole, have greater in vitro effectiveness against Mucorales and clinical evidence to support their use in mucormycosis(24)(25).

Posaconazole :

The in vitro activity of posaconazole against Mucorales varies according on the species. According to a study of 131 clinical isolates, posaconazole median MICs for different Mucorales species ranged from 1.0 g/mL to 8.0 g/mL. In laboratory animal studies, *Rhizopus* spp. infections were frequently non-responsive, whereas *Mucor* spp. infections responded to posaconazole the most. There is little clinical evidence on posaconazole's effectiveness in treating mucormycosis. Because of this, the oral suspension of posaconazole usually did not absorb properly, leading to treatment failures. To get beyond the pharmacokinetic constraints of the oral solution, a gastro-resistant tablet and an intravenous (IV) solution have been created. The tablet formulation is superior to the suspension formulation in a number of ways, including better bioavailability, which enables a once-daily dose, eliminates the need for food, and absorption that is unaffected by changes in gastric pH or motility. It also has less interpatient variability and more predictable plasma concentrations. As a salvage therapy for mucormycosis, posaconazole (oral suspension 400 mg2/day with meals, or 200 mg4/day if not taken with meals) is currently being investigated.(26)(27)(28)

Isavuconazole :

Isavuconazole, a novel broad-spectrum triazole, is the prodrug's biologically active ingredient. It is a vuconazoniumsulphate. It is authorised for the treatment of mucormycosis in the US. When Amphotericin B is not an option, it is permitted for the treatment of mucormycosis in Europe. With a loading dose of 200 mg three times day for two days and then 200 mg every day after that, it is available both intravenously and orally. Isavuconazole has a number of pharmacokinetic and safety advantages over other azoles, including linear pharmacokinetics, fewer drug-drug interactions, less toxicity, side effects on the skin and eyes, or QT prolongation; no nephrotoxic cyclodextrin in the IV formulation; and no need for dose adjustments in patients with kidney, liver, or obesity. Similar to posaconazole, isavuconazole has variable in vitro activity against Mucorales depending on the species. In clinical practise, it should be taken into account that the Mucorales MIC values of isavuconazole are 2- to 4-fold greater than those of posaconazole. According to multiple case reports, isavuconazole has been used successfully as a salvage therapy for mucormycosis in immunocompromised patients, including situations where posaconazole failed.(29)(30)(31)(32)

COMBINATIONAL THERAPY :

Mucormycosis in immunocompromised patients is increasingly being treated with a combination of antifungals, despite the absence of valid clinical data. The advantages of this therapeutic method are its synergistic impact and wider coverage, while its disadvantages include drug interactions, toxicity, cost, and antagonistic effects.(33)

In vitro and in vivo animal model studies have shown a synergy between polyenes and echinocandins. While inherently ineffective against Mucorales, in vitro echinocandins are thought to have some effect in vivo. This effect may be caused by the breakdown of a small amount of glucan on the fungus's cell wall, immune epitope

unmasking, or the promotion of phagocytosis. Compared to just 7 of 22 patients treated with ABLC alone, the combination of AMB+echinocandin was effective in 6 of 7 diabetic individuals with rhino-orbital or rhino-cerebral mucormycosis ($p=0.02$ in one retrospective study). There is conflicting evidence about the efficacy of the AMB+triazole combination in treating mucormycosis. In vitro studies on mice models of mucormycosis revealed synergy between a polyene and posaconazole, while in vivo research found no advantage from taking the medications at the same time. (34)(35)(36)

REFERENCES :

1. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoromycosis (zygomycosis) and nomenclature of the molecular mycologic perspectives. *Clinical Infectious Diseases*, 2012; 54(suppl_1): S8-1
2. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of (mucor-mycosis), France, 1997–2006. *Emerg Infect Dis.*, 2009; 15: 1395–1401.
3. Roden, M.M.; Zaoutis, T.E.; Buchanan, W.L.; Knudsen, T.A.; Sarkisova, T.A.; Schaufele, R.L.; Sein, M.; Sein, T.; Chiou, C.C.; Chu, J.H.; et al. Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases.
4. *Infect. Dis.* 2005, 41, 634–653. [CrossRef] Jeong, W.; Keighley, C.; Wolfe, R. Lee, W.L.; Slavin, M.A.; Kong, D.C.; Chen, S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. *Clin. Microbiol. Infect.* 2019, 25, 26–34 [CrossRef]
5. Skiada, A.; Pagano, L.; Groll, A.; Zimmerli, S.; Dupont, B.; Lagrou, K.; Lass-Flörl, C.; Bouza, E.; Klimko, N.; Gaustad, P.; et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. *Clin. Microbiol. Infect.* 2011, 17, 1859–1867. [CrossRef] [PubMed]
6. Hassan MI, Voigt K. Pathogenicity patterns of mucormycosis: Epidemiology, interaction with immune cells and virulence factors. *Med Mycol.* 2019; 57(2): 245–256.
7. About Mucormycosis" (<https://www.cdc.gov/fungal/diseases/mucormycosis/definition.h>. www.cdc.gov. May 25, 2021.
8. Riley TT, Muzny CA, Swiatlo E, Legendre DP (September 2016). "Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options". *The Annals of Pharmacotherapy*. 50 (9): 747–57. doi:10.1177/1060028016655425 (<https://doi.org/10.1177%2F1060028016655425>) . PMID 27307416 (<https://pubmed.ncbi.nlm.nih.gov/27307416>) . S2CID 22454217 (<https://api.semanticscholar.org/CorpusID:22454217>) .
9. Grossman ME, Fox LP, Kovarik C, Rosenbach M (2012). "1. Subcutaneous and deep mycoses: Zygomycosis/Mucormycosis" (<https://books.google.com/books?id=mqB4A-M9NY0C&pg=PA51>) . *Cutaneous Manifestations of Infection in the Immunocompromised Host* (2nd ed.). Springer. pp. 51–58. ISBN 978-1-4419-1577-1
10. "Symptoms of Mucormycosis" (<https://www.cdc.gov/fungal/diseases/mucormycosis/symptoms.html>. www.cdc.gov. January 11 2021. Retrieved May 25, 2021.

11. McDonald PJ. "Mucormycosis (Zygomycosis) Clinical Presentation: History and Physical
12. Lee S (2001). BrainChip for Microbiology v(<https://books.google.com/books?id=eSRfmX5QxogC&pg=PA70>) . Blackwell Science. p. 70. ISBN 0-632-04568Examination". (<https://emedicine.medscape.com/article/222551-clinical>) . emedicine.medscape.com. Retrieved May 28,2021-X.
13. Johnstone RB (2017). "25. Mycoses and Algal infections". Weedon's Skin Pathology Essentials
14. Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.; Chen, S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. *Clin. Microbiol. Infect.* 2019, 25, 26–34. [CrossRef]1.
15. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure external icon. *Clin Microbiol Infect.* 2009 Oct;15 Suppl 5:2-9.
16. Sivagnanam, S, Sengupta, DJ, Hoogestraat, D, Jain, R, Stednick, Z, Fredricks, DN, et al. [Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer center external icon](#). *Antimicrob Resist Infect Control.* 2017 November;6(1)
17. Walther, G.; Wagner, L.; Kurzai, O. Updates on the Taxonomy of Mucorales with an Emphasis on Clinically Important Taxa. *J. Fungi* 2019, 5, 106. [CrossRef]
18. Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.; Chen, S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. *Clin. Microbiol. Infect.* 2019, 25, 26–34. [CrossRef]
19. Chakrabarti, A.; Singh, R. Mucormycosis in India: Unique features. *Mycoses* 2014, 57 (Suppl. 3), 85–90. [CrossRef]
20. Xess, I.; Mohapatra, S.; Shivaprakash, M.R.; Chakrabarti, A.; Benny, G.L.; O'Donnell, K.; Padhye, A.A. Evidence Implicating *Thamnostylum lucknowense* as an Etiological Agent of Rhino-Orbital Mucormycosis. *J. Clin. Microbiol.* 2012, 50, 1491–1494. [CrossRef]
21. Chander, J.; Singla, N.; Kaur, M.; Punia, R.S.; Attri, A.; Alastruey-Izquierdo, A.; Stchigel, A.M.; Cano-Lira, J.F.; Guarro, J. *Saksena* erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections—A study from a tertiary care hospital in north India. *Infect. Dis.* 2017, 49, 170–177. [CrossRef]
22. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. *J Antimicrob Chemother.* 2003; 51(1): 45-52.
23. Lamoth F, Damonti L, Alexander BD. Role of antifungal susceptibility testing in non-*Aspergillus* invasive mold infections. *J Clin Microbiol.* 2016; 54(6): 1638-1640
24. Nagappan V, Deresinski S. Posaconazole: A broad-spectrum triazole antifungal agent. *Clin Infect Dis.* 2007; 45(12): 1610-1617.
25. Caramalho R, Maurer E, Binder U, Araújo R, Dolatabadi S, Lass-Flörl C, Lackner M. Etest cannot be recommended for in vitro susceptibility testing of Mucorales. *Antimicrob Agents Chemother.* 2015; 59(6): 3663-3665.
26. Lewis RE, Albert ND, Kontoyiannis DP. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. *Antimicrob Agents Chemother.* 2014; 58(11): 6767-6772.

- 27 Krishna G, Ma L, Martinho M, Preston RA, O'mara E. A new solid oral tablet formulation of posaconazole: A randomized clinical trial to investigate rising single-and multiple-dose pharmacokinetics and safety in healthy volunteers. *J Antimicrob Chemother.* 2012; 67(11): 2725-2730.
- 28 Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. *Antimicrob Agents Chemother.* 2014; 58(11): 6993-6995.
29. Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. *Antimicrob Agents Chemother.* 2015; 59(12): 7735-7742.
30. Peixoto D, Gagne LS, Hammond SP, Gilmore ET, Joyce AC, Soiffer RJ, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. *J Clin Microbiol.* 2014; 52(3): 1016-1019.
31. Graves B, Morrissey CO, Wei A, Coutsouvelis J, Ellis S, Pham A, et al. Isavuconazole as salvage therapy for mucormycosis. *Med Mycol Case Rep.* 2016; 11: 36-39.
32. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikos G, et al. Combination therapy for mucormycosis: Why, what, and how?. *Clin Infect Dis.* 2012; 54(1): 73-78
33. Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards Jr JE, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. *J Antimicrob Chemother.* 2016; 433.
34. Reed C, Bryant R, Ibrahim AS, Edwards Jr J, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. *Clin Infect Dis.* 2008; 47(3): 364-371.
35. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with hematologic malignancies and mucormycosis: A propensity score analysis. *Clin Microbiol Infect.* 2016; 22(9): 811-818.
36. Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of Amphotericin B, posaconazole and four other agents against *Rhizopus*. *J Antimicrob Chemother.* 2008; 61(3): 755-757.